David Koota, MD
Urology · East Brunswick, NJNPI 1548367006
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $799 of the $896 with a category attached, or 89.2%. It is spread thinly across 13 manufacturers, the largest accounting for just 22.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $392 and has fallen 86.1% since, to $54 in 2023. That places this record below the midpoint for urology clinicians in NJ, where the typical reported total is $2,095.
Across 59 payments — averaging $15.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$201
- AbbVie$198
- Astellas Pharma US Inc$121
- Ambu Inc.$111
- Dendreon Pharmaceuticals LLC$94
- Pfizer$56
- plus $115 from 7 others
Across 4 payments — averaging $87,499 each. An ownership or investment interest held by the physician or an immediate family member.
- Valencia Technologies Corporation$350K
What the payments were for
- Food & beverage$79989%
- Education$9711%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 14 | $201 |
| AbbVie(2 entities) | 19 | $198 |
| Astellas Pharma US Inc | 4 | $121 |
| Ambu Inc. | 4 | $111 |
| Dendreon Pharmaceuticals LLC | 6 | $94 |
| Pfizer | 4 | $56 |
| Bayer | 2 | $31 |
| Boston Scientific | 1 | $17 |
| Pacira Pharmaceuticals Incorporated | 1 | $15 |
| Merck | 1 | $15 |
| Janssen Scientific Affairs, LLC | 1 | $14 |
| Zyla Life Sciences, Inc. | 1 | $12 |
| Medtronic | 1 | $12 |
How this compares
$896 in reported general payments places this provider in the 25th percentile of 401 urology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 25 | $362,851 |
| MyrbetriqMirabegron | 238 | $230,138 |
| Abiraterone Acetate | 36 | $106,333 |
| Tamsulosin Hcl | 1,120 | $20,200 |
| PremarinEstrogens, Conjugated | 16 | $8,846 |
| Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl | 19 | $6,046 |
| Solifenacin Succinate | 72 | $5,914 |
| Finasteride | 368 | $5,606 |
| Testosterone Cypionate | 81 | $5,003 |
| Potassium Citrate ErPotassium Citrate | 32 | $4,980 |
| Desmopressin Acetate | 32 | $4,575 |
| Oxybutynin Chloride ErOxybutynin Chloride | 152 | $3,823 |
| Methenamine Hippurate | 30 | $3,556 |
| Dutasteride | 93 | $3,404 |
| Silodosin | 23 | $3,058 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $121 | $592,989263 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $14 | $106,33336 claims |
| PfizerPremarin | $56 | $8,84616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 401 urology providers in New Jersey.
Other urology in East Brunswick
- Michael StifelmanHackensack$1.4M
- Gordon BrownCherry Hill$1.3M
- Thomas MuellerLinwood$1.1M
- David SussmanLinwood$802K
- Michael IngberDenville$530K
- Ravi MunverHackensack$529K
- Grannum SantBridgewater$487K
- Mutahar AhmedMaywood$414K
- Kevin GioiaRumson$143K
- Robert SimonCliffside Park$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.